Jonas Agerlund Povlsen1, Bo Løfgren2, Christian Dalgas2, Nichlas Riise Jespersen2, Jacob Johnsen2, Hans Erik Bøtker2. 1. Department of Cardiology, Aarhus University Hospital, Brendstrupgaardsvej 100, 8200 Aarhus N, Denmark; Institute of Clinical Medicine, Aarhus University, Brendstrupgaardsvej 100, 8200 Aarhus N, Denmark. Electronic address: jonas.povlsen@ki.au.dk. 2. Department of Cardiology, Aarhus University Hospital, Brendstrupgaardsvej 100, 8200 Aarhus N, Denmark; Institute of Clinical Medicine, Aarhus University, Brendstrupgaardsvej 100, 8200 Aarhus N, Denmark.
Abstract
BACKGROUND: Reperfusion injury and its modulation are incompletely characterized. The purpose of the present study was to characterize the dynamics of reperfusion injury by portraying the temporal release of lactate dehydrogenase (LDH) during ischemia-reperfusion injury in an isolated heart model. METHODS: We studied infarct size and LDH release in the following groups: I) Effect of reperfusion length was evaluated in 79 rats subjected to 40 minute ischemia and 60, 90, 120 or 180 minute reperfusion and a) ischemic preconditioning (IPC) or b) No IPC (control). II) LDH release kinetics was studied in 6 rats subjected to calcium-paradox to verify the applicability of LDH as a dynamic marker of cellular injury. III) Ischemia-reperfusion injury modification was studied in 36 rats subjected to: a) ischemic postconditioning, b) prolonged ischemia, c) Reperfusion Injury Salvage Kinase (RISK) pathway inhibition with wortmannin in IPC hearts, d) RISK activation with insulin or e) mitochondrial permeability transition pore (mPTP) inhibition with cyclosporine A. RESULTS: Infarct size increased from 60 to 180 minute reperfusion in control hearts. LDH was released in two separate peaks from 2 to 20 and 30 to 120 min of reperfusion. IPC attenuated both peaks. Postconditioning and agents known to modify reperfusion injury attenuated the second peak. CONCLUSIONS: Frequent measurement of myocardial ischemia markers for 120 min of reperfusion allows identification of two phases of reperfusion injury that are affected by cardioprotective stimuli. The second phase contributes significantly to final infarct size, which is modifiable and a potential target for cardioprotective interventions.
BACKGROUND:Reperfusion injury and its modulation are incompletely characterized. The purpose of the present study was to characterize the dynamics of reperfusion injury by portraying the temporal release of lactate dehydrogenase (LDH) during ischemia-reperfusion injury in an isolated heart model. METHODS: We studied infarct size and LDH release in the following groups: I) Effect of reperfusion length was evaluated in 79 rats subjected to 40 minute ischemia and 60, 90, 120 or 180 minute reperfusion and a) ischemic preconditioning (IPC) or b) No IPC (control). II) LDH release kinetics was studied in 6 rats subjected to calcium-paradox to verify the applicability of LDH as a dynamic marker of cellular injury. III) Ischemia-reperfusion injury modification was studied in 36 rats subjected to: a) ischemic postconditioning, b) prolonged ischemia, c) Reperfusion Injury Salvage Kinase (RISK) pathway inhibition with wortmannin in IPC hearts, d) RISK activation with insulin or e) mitochondrial permeability transition pore (mPTP) inhibition with cyclosporine A. RESULTS:Infarct size increased from 60 to 180 minute reperfusion in control hearts. LDH was released in two separate peaks from 2 to 20 and 30 to 120 min of reperfusion. IPC attenuated both peaks. Postconditioning and agents known to modify reperfusion injury attenuated the second peak. CONCLUSIONS: Frequent measurement of myocardial ischemia markers for 120 min of reperfusion allows identification of two phases of reperfusion injury that are affected by cardioprotective stimuli. The second phase contributes significantly to final infarct size, which is modifiable and a potential target for cardioprotective interventions.
Authors: Hans Erik Bøtker; Derek Hausenloy; Ioanna Andreadou; Salvatore Antonucci; Kerstin Boengler; Sean M Davidson; Soni Deshwal; Yvan Devaux; Fabio Di Lisa; Moises Di Sante; Panagiotis Efentakis; Saveria Femminò; David García-Dorado; Zoltán Giricz; Borja Ibanez; Efstathios Iliodromitis; Nina Kaludercic; Petra Kleinbongard; Markus Neuhäuser; Michel Ovize; Pasquale Pagliaro; Michael Rahbek-Schmidt; Marisol Ruiz-Meana; Klaus-Dieter Schlüter; Rainer Schulz; Andreas Skyschally; Catherine Wilder; Derek M Yellon; Peter Ferdinandy; Gerd Heusch Journal: Basic Res Cardiol Date: 2018-08-17 Impact factor: 17.165
Authors: Joachim Nielsen; Jacob Johnsen; Kasper Pryds; Niels Ørtenblad; Hans Erik Bøtker Journal: J Muscle Res Cell Motil Date: 2019-10-19 Impact factor: 2.698
Authors: Sandrine Lecour; Hans E Bøtker; Gianluigi Condorelli; Sean M Davidson; David Garcia-Dorado; Felix B Engel; Peter Ferdinandy; Gerd Heusch; Rosalinda Madonna; Michel Ovize; Marisol Ruiz-Meana; Rainer Schulz; Joost P G Sluijter; Linda W Van Laake; Derek M Yellon; Derek J Hausenloy Journal: Cardiovasc Res Date: 2014-10-24 Impact factor: 10.787
Authors: Veronika Barsukevich; Marina Basalay; Jenifer Sanchez; Alexander Mrochek; John Whittle; Gareth L Ackland; Alexander V Gourine; Andrey Gourine Journal: Basic Res Cardiol Date: 2014-12-02 Impact factor: 17.165
Authors: Jan Hansen; Jacob Johnsen; Jan Møller Nielsen; Charlotte Brandt Sørensen; Casper Carlsen Elkjær; Nichlas Riise Jespersen; Hans Erik Bøtker Journal: Drug Des Devel Ther Date: 2020-07-02 Impact factor: 4.162
Authors: Jack J Miller; Angus Z Lau; Per Mose Nielsen; Giles McMullen-Klein; Andrew J Lewis; Nichlas Riise Jespersen; Vicky Ball; Ferdia A Gallagher; Carolyn A Carr; Christoffer Laustsen; Hans Erik Bøtker; Damian J Tyler; Marie A Schroeder Journal: JACC Cardiovasc Imaging Date: 2017-12-13